6709 Stock Overview
Engages in the research and development of vaccine technology and related products in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Advagene Biopharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$19.80 |
| 52 Week High | NT$30.00 |
| 52 Week Low | NT$16.40 |
| Beta | 0.69 |
| 11 Month Change | -19.18% |
| 3 Month Change | -20.16% |
| 1 Year Change | -23.85% |
| 33 Year Change | -59.09% |
| 5 Year Change | 1.02% |
| Change since IPO | -24.71% |
Recent News & Updates
Shareholder Returns
| 6709 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -5.9% | 1.4% | 0.8% |
| 1Y | -23.8% | 7.5% | 30.3% |
Return vs Industry: 6709 underperformed the TW Pharmaceuticals industry which returned 7.5% over the past year.
Return vs Market: 6709 underperformed the TW Market which returned 30.3% over the past year.
Price Volatility
| 6709 volatility | |
|---|---|
| 6709 Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 3.6% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6709 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6709's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 11 | Yu-Shen Hsu | www.advagene.com.tw |
Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. Its products in development include nasal spray influenza vaccine, allergy vaccines, and COVID-19 immunotherapy. The company is based in Taipei, Taiwan.
Advagene Biopharma Co., Ltd. Fundamentals Summary
| 6709 fundamental statistics | |
|---|---|
| Market cap | NT$1.18b |
| Earnings (TTM) | -NT$76.89m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-15.3x
P/E RatioIs 6709 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6709 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$76.89m |
| Earnings | -NT$76.89m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.29 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 6709 perform over the long term?
See historical performance and comparison